News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,769 Results
Type
Article (40675)
Company Profile (270)
Press Release (676818)
Multimedia
Podcasts (76)
Webinars (17)
Section
Business (204563)
Career Advice (2018)
Deals (35506)
Drug Delivery (105)
Drug Development (81312)
Employer Resources (173)
FDA (16372)
Job Trends (14929)
News (346153)
Policy (32700)
Tag
Academia (2558)
Accelerated approval (23)
Adcomms (24)
Allergies (123)
Alliances (49574)
ALS (157)
Alzheimer's disease (1622)
Antibody-drug conjugate (ADC) (265)
Approvals (16558)
Artificial intelligence (454)
Autoimmune disease (115)
Automation (33)
Bankruptcy (361)
Best Places to Work (11638)
BIOSECURE Act (20)
Biosimilars (173)
Biotechnology (176)
Bladder cancer (147)
Brain cancer (51)
Breast cancer (587)
Cancer (4391)
Cardiovascular disease (358)
Career advice (1700)
Career pathing (34)
CAR-T (261)
CDC (44)
Celiac Disease (1)
Cell therapy (682)
Cervical cancer (34)
Clinical research (69001)
Collaboration (1465)
Company closure (4)
Compensation (1039)
Complete response letters (46)
COVID-19 (2694)
CRISPR (81)
C-suite (685)
Cystic fibrosis (136)
Data (5682)
Decentralized trials (2)
Denatured (25)
Depression (112)
Diabetes (455)
Diagnostics (6601)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (213)
Drug pricing (166)
Drug shortages (28)
Duchenne muscular dystrophy (211)
Earnings (89728)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116574)
Executive appointments (937)
FDA (19111)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1320)
Gene editing (180)
Generative AI (38)
Gene therapy (538)
GLP-1 (912)
Government (4624)
Grass and pollen (6)
Guidances (376)
Healthcare (18858)
HIV (48)
Huntington's disease (39)
IgA nephropathy (75)
Immunology and inflammation (229)
Immuno-oncology (36)
Indications (76)
Infectious disease (2934)
Inflammatory bowel disease (178)
Inflation Reduction Act (13)
Influenza (100)
Intellectual property (209)
Interviews (315)
IPO (16621)
IRA (48)
Job creations (3640)
Job search strategy (1427)
Kidney cancer (15)
Labor market (79)
Layoffs (541)
Leadership (28)
Legal (7941)
Liver cancer (88)
Longevity (12)
Lung cancer (606)
Lymphoma (349)
Machine learning (37)
Management (59)
Manufacturing (669)
MASH (152)
Medical device (13686)
Medtech (13723)
Mergers & acquisitions (19846)
Metabolic disorders (1137)
Multiple sclerosis (143)
NASH (16)
Neurodegenerative disease (276)
Neuropsychiatric disorders (69)
Neuroscience (2700)
NextGen: Class of 2025 (6518)
Non-profit (4501)
Now hiring (60)
Obesity (527)
Opinion (248)
Ovarian cancer (149)
Pain (173)
Pancreatic cancer (190)
Parkinson's disease (251)
Partnered (31)
Patents (444)
Patient recruitment (391)
Peanut (54)
People (58519)
Pharmaceutical (63)
Pharmacy benefit managers (26)
Phase I (21501)
Phase II (30373)
Phase III (22645)
Pipeline (3800)
Policy (260)
Postmarket research (2564)
Preclinical (9162)
Press Release (64)
Prostate cancer (214)
Psychedelics (43)
Radiopharmaceuticals (264)
Rare diseases (709)
Real estate (5948)
Recruiting (69)
Regulatory (23930)
Reports (51)
Research institute (2372)
Resumes & cover letters (351)
Rett syndrome (23)
RNA editing (12)
RSV (73)
Schizophrenia (134)
Series A (216)
Series B (165)
Service/supplier (11)
Sickle cell disease (91)
Special edition (20)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3607)
State (2)
Stomach cancer (16)
Supply chain (97)
Tariffs (80)
The Weekly (49)
Vaccines (944)
Venture capital (74)
Weight loss (340)
Women's health (74)
Worklife (17)
Date
Today (122)
Last 7 days (530)
Last 30 days (2388)
Last 365 days (30273)
2025 (29664)
2024 (35220)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (734)
Alabama (77)
Alaska (7)
Arizona (288)
Arkansas (13)
Asia (38937)
Australia (6363)
California (10387)
Canada (3086)
China (971)
Colorado (433)
Connecticut (445)
Delaware (307)
Europe (83929)
Florida (1538)
Georgia (330)
Hawaii (2)
Idaho (61)
Illinois (780)
India (54)
Indiana (491)
Iowa (20)
Japan (362)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1305)
Massachusetts (7485)
Michigan (301)
Minnesota (585)
Mississippi (5)
Missouri (120)
Montana (30)
Nebraska (26)
Nevada (112)
New Hampshire (73)
New Jersey (2802)
New Mexico (28)
New York (2766)
North Carolina (1355)
North Dakota (8)
Northern California (4986)
Ohio (305)
Oklahoma (20)
Oregon (38)
Pennsylvania (2129)
Puerto Rico (19)
Rhode Island (45)
South America (1100)
South Carolina (58)
South Dakota (1)
Southern California (4020)
Tennessee (163)
Texas (1600)
United States (37103)
Utah (306)
Vermont (1)
Virginia (238)
Washington D.C. (78)
Washington State (851)
West Virginia (4)
Wisconsin (90)
Wyoming (2)
717,769 Results for "inhibrx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Inhibrx Announces Participation in Upcoming Scientific Conferences
November 4, 2025
·
2 min read
Press Releases
Inhibrx Reports Third Quarter 2025 Financial Results
November 14, 2025
·
7 min read
Press Releases
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
December 17, 2025
·
7 min read
Press Releases
Inhibrx Reports Second Quarter 2025 Financial Results
August 14, 2025
·
8 min read
Press Releases
Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
October 22, 2025
·
5 min read
Press Releases
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
October 23, 2025
·
12 min read
Biotech Beach
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
Inhibrx, Inc. announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. to holders of shares of the Company’s common stock on a pro rata basis.
May 10, 2024
·
12 min read
Press Releases
Inhibrx Reports First Quarter 2025 Financial Results
May 15, 2025
·
7 min read
Deals
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities..
May 30, 2024
·
5 min read
Biotech Beach
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Inhibrx, Inc. announced that, at a special meeting, the Company’s stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
May 24, 2024
·
9 min read
1 of 71,777
Next
